Mast cell leukemia (MCL) is a rare form of aggressive mastocytosis with a reported median survival below 6 months. Casuistic reports suggest the effectiveness of allogeneic bone marrow transplantation (BMT) for MCL. However, these reports lack clear evidence for a graftversus-mast-cell (GvMC) effect. We prospectively investigated the GvMC at different time points after allogeneic BMT and donor-lymphocyte infusions (DLI). Samples were gathered from a patient with MCL treated with allogeneic BMT from an unrelated HLA identical donor. Parameters for detection of a GvMC effect included flow cytometrical analysis of mast cell (MC) populations in peripheral blood and BM, BM smear and histology, chimerism analysis of flow cytometrically sorted BM CD117 þ /CD34À MC and testing for anti-mast cell reactivity of donor lymphocytes by interferon (IFN)-c ELISPOT. DLIs reduced MC from 5 to 0.5%. MC chimerism analysis demonstrated a complete recipient genotype after BMT, suggesting that the persistent mastocytosis was part of residual neoplastic disease. At 3.7 years after BMT, there is some evidence for relapse. In summary, BMT and DLIs attenuated the mastocytosis from an aggressive to an indolent form and may have improved the patients' prognosis. The in vitro data of our study indicate for the first time the existence of a GvMC effect.
Mastocytosis is a rare hematological disorder that comprises a heterogeneous spectrum of clinical pictures, ranging from indolent to very aggressive forms like mast cell leukemia (MCL). 1 So far, there is no curative treatment for MCL. All patients with MCL who received chemotherapeutic agents did poorly with an overall survival of less than 1 year, despite transient remissions in some cases. [2] [3] [4] [5] [6] Somatic mutations in c-kit appear to be involved in the pathogenesis of mast cell (MC) disorders; however, the c-kit tyrosine kinase inhibitors that are currently available probably have a very limited role in management of the common forms of mastocytosis, which is still under investigation. 7, 8 Allogeneic bone marrow transplantation (BMT) may be a curative therapeutic approach in MCL for three reasons: (1) MC originate from a BM hematopoietic CD117 þ /CD34 þ stem cell and demonstrate a number of characteristics that indicate they are myeloid cells. 9, 10 (2) The involvement of a multipotential hematopoietic progenitor cell in MC disorders is very likely, since in patients with systemic mastocytosis c-kit mutations can be detected not only in the MC but also in other myeloid cells, CD34 þ progenitors and even in B lymphocytes. 10 (3) Antigenic alterations such as point mutations of c-kit in MC may constitute a target for recognition by the donor-derived T cells and allow for a graft-versus-mast-cell effect (GvMC).
Patient and methods

Patient and clinical follow-up
A 31-year-old man was admitted to our hospital because of splenomegaly and B symptoms. The patient reported a 2 year history of episodic abdominal cramps, which over the past 2 months were accompanied by progressive fatigue, weight loss of about 10 kg and several episodes of pruritus and hypotension resulting in syncope. On presentation, physical examination showed a marked hepatomegaly (21 cm in medioclavicular line), splenomegaly (22 cm in length) and abdominal lymphadenopathy. CBC was normal (Hb 12.1 g/dl, PLT 257 000/ml, WBC 8400/ml). The differential count showed 70% segmented neutrophils, 7% basophil-like cells, 1% bands, 18% lymphocytes and 4% monocytes. Bone marrow (BM) smear and biopsy showed a hypercellular marrow diffusely infiltrated (50%, focally more) with small or medium sized 'monocytoid' cells displaying signs of granulation.
Additional subtle signs of myelodysplasia and a slight increase of blasts with basophilic granules (5%) were seen but the criteria for MDS or AML were not fulfilled. RT-PCR analysis for bcr/abl was negative. Cytogenetic analysis of the BM cells showed a translocation t(13;14) (q10;q10), which on further analysis proved to represent a constitutional Robertsonian translocation inherited from the patient's mother. This peculiar clinical and blood picture was interpreted as a Ph-negative myeloproliferative syndrome. No special therapy was given and the patient was set up on observation. During the next few weeks, the patient complained of low-grade intermittent fever, night sweats, progressive fatigue, episodic upper abdominal cramps and persistent left upper abdominal discomfort. At 2 months after the first admission, a deterioration of the CBC was noted (WBC 20 000/ml, 16% basophil-like cells, Hb 10.5 g/dl, PLT 147000/ml). A follow-up BM smear and biopsy showed a diffuse infiltration (with focal accumulation) by monocytoid cells altering the normal BM architecture (Figure 1f ). Although most of the infiltrating cells exhibited an eccentrically oval nucleus with condensed chromatin, some had polylobular nuclei or were more blastic in appearance exhibiting an increased nucleus/cytoplasm (N/C) ratio and a fine, immature chromatin pattern in their nucleus. Graft-versus-mast-cell effect after BMT A Spyridonidis et al blood demonstrated 11% circulating mast cells (MC) (Figure 1f) . The 24 h-urine histamine was subsequently tested and was high (1165 mg/l, upper limit of normal: 35 mg/l). No c-kit mutations at codon 816 (A816 V) or at codon 560 (V560G) were detected. The patient was diagnosed with MCL. Owing to the patient's clinical deterioration due to disease progression, the dismal prognosis and his young age, he was considered for an allogeneic bone marrow transplant (BMT). After extensive discussion with the patient about the experimental character of BMT in mast cell disorders, he opted for this treatment. The conditioning chemotherapy was standard busulfan (16 mg/kg p.o.)/cyclophosphamide (2 Â 60 mg/kg i.v.) regime. GVHD prophylaxis consisted of anti-T-cell-globulin ATG-S s (Fresenius, Graefeling, Germany) (20 mg/kg/dy for 3 days) in addition to cyclosporin A and a short course of methotrexate. The patient received 4 Â 10 8 /kg BM mononuclear cells (MNC) harvested from an unrelated, HLA-matched female donor. Stable neutrophil counts 41000/ml and platelet counts 450 000/ml were reached on days þ 15 and þ 36, respectively. The early post transplantation period was complicated by abdominal cramps, which correlated with the abrupt decrease of histamine levels. The patient did not develop GVHD and cyclosporin A prophylaxis was discontinued on day þ 157.
Since on day þ 988 MC were still detected in the BM, low-dose interferon (IFN)-a (Roferon s , Roche, three injections at 3 million units between days þ 995 and þ 999) was given but not tolerated and therefore discontinued. We administered DLIs (1 Â 10 6 CD3 þ cells/kg b.w. on days þ 1093 and þ 1124, 5 Â 10 6 CD3 þ cells/kg b.w. on day þ 1187) without any adverse effects. At the last examination, nearly 3.7 years after BMT, the patient remains in excellent condition and is fully active.
Flow cytometry, chimerism analysis and ELISPOT
Flow cytometry studies were conducted with a FACScan (Becton Dickinson), and cell-sorting experiments were performed with a MoFlow Cell-Sorter (Cytomation). Flow cytometric detection and enumeration of BM MC was based on their high expression of CD117 (c-kit) and their negative expression of CD34 antigen. Furthermore, multicolor flow cytometry was applied to test the aberrant expression of CD25 on CD117 þ /CD34À BM MC. CD117 þ /CD34À BM MC isolated by flow cytometric cell sorting were investigated by PCR-based microsatellite chimerism analysis (THO-1 marker). Mixed lymphocyte reaction (MLR) was applied to induce a polyclonal stimulation of donor PBMC, to detect alloreactive, MCspecific T cells. CD117 þ /CD34À MC were cocultivated with fresh PBMC of donor origin isolated from the patient's blood at a ratio of 1:5 in a microtiter plate. After prestimulation of donor lymphocytes with sorted CD117 þ /CD34À MC from recipient origin (day 1275), donor cells were tested for specific IFN-g secretion in an ELISPOT assay. At day 10, T cells were restimulated with patient MC or with pre-Tx patient BM cells in split-well analyses to test for specific IFN-g secretion in an ELISPOT assay.
Results
Diagnosis of MCL
The diagnosis of MCL was based on the diffuse infiltration of BM with cytologically atypical MC (mast cells type II and metachromatic blasts), the presence of 410% MC in the peripheral blood, the elevated urine histamine levels, the absence of urticaria pigmentosa and the rapidly progressive cytopenia and B symptoms (weight loss, fever, night sweats, fatigue). 1 
Follow up of BM mastocytosis after BMT
Flow cytometry of the BM aspirate before BMT revealed about 14% CD117 þ /CD34À MC, which exhibited a homogenous distribution in the light scatter gate (Figure  1d, e) . BM biopsies on days day þ 30 and day þ 100 after BMT demonstrated a decreased but still persistent focal infiltration with atypical MC. Flow cytometrical quantification revealed 5% CD117 þ /CD34À MC with the same scatter characteristics (Figure 1d,e) . This residual MC population correlated with the total histamine levels in 24 h urine, remaining slightly above the upper normal limit reflecting a residual burden of MC (Figure 1c) . Immunsuppressive prophylaxis was discontinued on day þ 157. A flow cytometrical BM examination 1 year after BMT revealed a further reduction of MC; however, 2.4% CD117 þ /CD34À MC were still present (normal: o0.008%). Unexpectedly, the light scatter distribution of the gated CD117 þ /CD34À MC demonstrated larger and more granulated cells, correlating with the more mature and typical MC morphology seen in the BM biopsy and aspirate (Figure 1f ). Further immunophenotyping revealed the expression of CD25, suggesting the nonreactive nature of the MC (not shown).
Since on day þ 988 MC were still detected in the BM (approx. 15% in the BM biopsy and 2.5% in the FACS analysis), we administered DLIs (1 Â 10 6 CD3 þ cells/kg b.w.) on day þ 1093 and day þ 1124. No GVHD was seen. Control BM examination on day þ 1185 demonstrated a marked decrease of recipient MC, both in the BM biopsy (less than 5%) as well as in the FACS analysis of the BM aspirate (0.5% MC, Figure 1 ). Additionally, a notable decrease of the 24 h urine histamine level to nearly normal levels was detected (Figure 1a) . Note the strong correlation between number of CD117 þ /CD34À cells in the BM and serum histamine levels. We gave 5 Â 10 6 CD3 þ cells/kg b.w. on day þ 1187 without any adverse effects. On day þ 1275, about 100 days after the last DLI administration, 1.6% mature, recipient MC were detected in the BM (Figure 1d, f, g ).
Donor lymphocyte stimulation
After prestimulation of donor lymphocytes with sorted CD117 þ /CD34À MC from recipient origin (day 1275), donor cells were tested for specific IFN-g secretion in an ELISPOT assay. Donor cells did acquire a stimulated phenotype, but we were not able to detect IFN-g secretion Graft-versus-mast-cell effect after BMT A Spyridonidis et al of the prestimulated lymphocytes against the MC in any of 10 wells.
Chimerism analysis
We isolated CD117 þ /CD34À BM MC by flow cytometric cell sorting on day þ 604 and day þ 1275 post-BMT and investigated their origin by PCR-based microsatellite chimerism analysis. Whereas in the whole BM mononuclear cells a complete donor chimerism was found, the purified MC were demonstrated to be completely recipient derived as depicted in Figure 1g .
Discussion
Mast cell leukemia is a rare form of aggressive mastocytosis with a very unfavorable prognosis and a reported median survival of less than 6 months. [1] [2] [3] [4] [5] [6] Myeloablative allogeneic BMT has been attempted in at least one case of very aggressive MC disease with a novel c-kit mutation; however, the patient died within 4 months after the BMT. 11 In two other cases of systemic mastocytosis with associated MDS/AML treated with allogeneic BMT, the BM and liver mastocytosis persisted despite the complete remission of the associated hematological disease. 12, 13 However, in one of these cases, the authors could demonstrate that the genotype of the MC isolated from the BM switched from recipient to donor on day þ 198 post transplantation, and, therefore, they suggested that MC proliferation in BM was rather a reactive process than part of the neoplastic disease. 13 In our patient, residual BM mastocytosis and splenomegaly persisted during the whole observation period. The fact that the purified BM MC revealed a recipient genotype post transplant (up to day þ 1275), and that immunophenotyping revealed an aberrant expression of CD25, renders the hypothesis of a reactive process unlikely. Aberrant CD25 expression on CD117 þ /CD34À BM MC has been recently introduced as a disease criterion for the diagnosis of mast cell diseases. Normal or reactive BM MC do not express CD25, whereas neoplastic MC very frequently express CD25. 1 Several observations support the therapeutic role of BMT and DLIs in this patient: First, conditioning resulted to a marked decrease of BM MC. However, 5.5% MC were still detected by flow cytometry at day 100 after BMT. Further decrease of MC was evident at later time points, after discontinuation of the immunsupression. After DLIs, a further decrease of MC and histamine levels was observed. Thus, a clear temporal relationship between immunsuppression withdrawal or DLI administration and the reduction in MC numbers in the BM and the histamine levels in 24 h urine was observed, indicating the slow but constant GvMC effect.
During the follow-up, MC changed to a more mature morphology with only a small percentage displaying atypical cytological features, the histamine levels remained stable at low levels, and the patient kept a very good performance status with no symptoms. Apparently, BMT shifted the mastocytosis from an aggressive to a more indolent form and may have improved the prognosis of our patient.
The hypothesis that BMT eliminated a mastocytosis clone with aggressive features but could not completely eradicate a more indolent mastocytosis clone(s) in our patient is supported by cytological studies and flow cytometry analysis of BM MC. The aggressive mastocytosis clone (amc) could clearly be identified by flow cytometry based on its distinct and homogenous light scatter characteristics (Figure 1d, e) . In contrast, MC examined at later time points after BMT revealed heterogenous and higher light scatter properties, reflecting their mature morphology seen in histological studies (Figure 1f) . Of great interest is the observation that although MC with amc-typical light scatter characteristics decreased after conditioning therapy, they persisted at a constant level of 5% up to day 100 after BMT. At later time points, no MC were found in the amc-light scatter gate. This long time period from pretransplantation preparative chemotherapy to complete eradication of MC with amc-typical characteristics (4100 days) is strongly indicative for a graft effect against the aggressive MC clone. At later time points, the numbers of recipient MC with heterogenous and high light scatter characteristics remained constant at about 2.5% for an observation period of about 2 years (days þ 368-days þ 988). After DLIs, a marked decrease of MC and histamine levels was observed, suggesting a GvMC effect against these nonaggressive MC. However, the three DLIs could not eradicate the indolent mastocytosis, and recipient MC, which probably were not recognized by T cells, were still detectable on day þ 1275. This corresponds to our in vitro data, which showed activation, but no IFN-g secretion, by PBMC of donor origin after stimulation with sorted BM MC from day 1275. However, this could also be attributable to the low sensitivity of the assay, since only 10 wells could be set up due to scarcity of available cells, and the donor cells did acquire a stimulated phenotype but did not multiply in culture, so less than 5 Â 10 4 cells/well could be tested in the ELISPOT.
In summary, BMT may be considered as a therapeutic approach in MCL or other aggressive forms of systemic mastocytosis. Attention should be paid to mediator release symptoms, which can complicate the early post transplant period. Our data support the concept of the existence of a GvMC effect.
